Physicians' Academy for Cardiovascular Education
The ROSE2 trial with obecitrapib in combination with ezetimbe as an adjunct to high-intensity statin met its primary endpoint of LDL-c reduction.
The goal of LDL-c management is to reduce long-term CVD risk. Statins form the foundation of lipid-lowering therapy, but more ammunition is needed to attain LDL-c goals in all patients. This series of 3 presentations discusses current and evolving therapeutic LDL-c lowering options.
What is the rationale for CETP inhibition? Does it have the potential to lower the risk of CHD in addition to high-intensity statin therapy? What have we learned from previous CETP inhibitor outcome trials? and what trials can we expect in the near future? In this series of three presentations, you will be provided with novel insights on CETP inhibition.
Prof. Ray presents the results of the ROSE trial, which demonstrated that the CETP inhibitor obicetrapib lowers LDL-c in patients on high intensity statins.
Prof. Nicholls reviews previous studies with different CETP inhibitors and presents details about ongoing studies with the CETP inhibitor obicetrapib.
"It has become apparent that the reduction in atherogenic lipoproteins drives CHD protection by CETP inhibition - not changes in HDL-c", says Prof. Kastelein. He explains this statement by findings from studies.
EAS 2022 Treatment with the CETP inhibitor obicetrapib resulted in a dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.
EAS 2022 Prof. Ray shares the topline results of the ROSE trial, in which the effect of obicetrapib was examined in patients with elevated LDL-c despite high-intensity statin treatment.
Educational slides on the emerging role of CETP inhibition in the management of cardiovascular disease
The benefit of the CETP inhibitor anacetrapib on major coronary events increases with longer follow-up, shown in a post-trial analysis of patients who had been randomized to anacetrapib compared to those on placebo in the REVEAL trial.
AHA 2021 Treatment with the CETP inhibitor obicetrapib resulted in dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.
In the past, there has been confusion about the relationship between HDL-c and CV risk and also between triglycerides and CV risk. Prof. Libby gives an update on what we know now about these lipids and CV risk.
